Paper - WANFANG MED ONLINE

You Position: Home > Paper

从肺功能改善看慢性阻塞性肺疾病的治疗进展

( views:580, downloads:1239 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 4

DOI:: 10.3760/cma.j.issn.1001-0939.2019.04.019

Key Word:: No keyword available

Abstract：在我国,慢性阻塞性肺疾病(慢阻肺)是一种高罹患率和病死率的慢性疾病,肺功能检测不仅是诊断该病的客观标准,而且对评估疾病严重程度、急性加重风险、临床管理疗效、疾病进展速度和预后等方面具有重要的参考价值.其多种管理策略中,吸入治疗是缓解症状、降低急性加重风险、改善肺功能、提高生活质量和改善预后的重要措施,其中长效M-受体阻断剂[(LAMA)、β2-受体激动剂(LABA)和吸入性糖皮质激素(ICS)的长效双联制剂LAMA/LABA及三联制剂LAMA/LABA/ICS对慢阻肺患者有明显疗效.

Reference

[1]Gregory J. Feldman,Ana R. Sousa,David A. Lipson,etc.Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study[J].2017,34(11).
[2]Thierry, Perez,Pierre Régis, Burgel,Jean-Louis, Paillasseur,etc.Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease.[J].2015,10.
[3]Edward M, Kerwin,Chris J, Kalberg,Dmitry V, Galkin,etc.Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.[J].2017,12(Spec ).
[4]Lipson, David A.,Barnhart, Frank,Brealey, Noushin,etc.Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD[J].2018,378(18).
[5]Yuji,Oba.Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.[J].2018,12.
[6]Wang, Chen,Xu, Jianying,Yang, Lan,etc.Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J].2018,391(10131).
[7]S, Appleton,T, Jones,P, Poole,etc.Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease.[J].2006,(3).
[8]Horita, Nobuyuki,Nagashima, Akimichi,Kaneko, Takeshi.Long-Acting beta-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD[J].2017,318(13).
[9]Afisi Segun, Ismaila,Eline L, Huisman,Yogesh Suresh, Punekar,etc.Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.[J].2015,10.
[10]Bateman,E.D.,Ferguson,G.T.,Barnes,N.,etc.Dual bronchodilation with QVA149 versus single bronchodilator therapy: The SHINE study[J].2013,42(6).
[11]Imran Naeem Abbasi,Adeel Ahsan,Asaad Ahmed Nafees.Correlation of respiratory symptoms and spirometric lung patterns in a rural community setting, Sindh, Pakistan: a cross sectional survey[J].2012,12.
[12]Marc L Decramer,Kenneth R Chapman,Ronald Dahl,etc.Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study[J].2013,1(7).
[13]Calzetta, Luigino,Rogliani, Paola,Matera, Maria Gabriella,etc.A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD[J].2016,149(5).
[14]Pedone,C.,Scarlata,S.,Bellia,V.,etc.Alternative ways of expressing FEV1 and mortality in elderly people with and without COPD[J].2013,41(4).
[15]Exuzides, Alex,Colby, Chris,Briggs, Andrew H.,etc.Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study[J].2017,37(4).
[16]钟南山.2017年慢性气道疾病防治研究进展[J].2018,(1).
[17]M Reza, Maleki-Yazdi,Dave, Singh,Antonio, Anzueto,etc.Assessing Short-term Deterioration in Maintenance-na?ve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.[J].2017,33(12).
[18]Pere, Almagro,Pablo, Martinez-Camblor,Joan B, Soriano,etc.Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.[J].2014,9(2).
[19]Edward Kerwin,Gary T. Ferguson,Shahin Sanjar,etc.Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies[J].2017,195(6).
[20]Jinping,Zheng,Nanshan,Zhong,Changzheng,Wang,etc.The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).[J].2018.
[21]Donohue, James F.,Jones, Paul W.,Bartels, Christian,etc.Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease[J].2018,49.
[22]M. Reza Maleki-Yazdi,Mathieu Molimard,Dorothy L. Keininger,etc.Cost Effectiveness of the Long-Acting P2-Adrenergic Agonist (L ABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LAB A/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstru[J].2016,14(5).
[23]Veale, Antony,Hebert, Jacques,Tetzlaff, Kay,etc.Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)[J].2015,45(4).
[24]Alvar Agusti,Peter MA Calverley,Bartolome Celli,etc.Characterisation of COPD heterogeneity in the ECLIPSE cohort[J].2010,11(1).